C71T
CANCELLED SECTION 71
26/06/2026
Voltar para busca
Dado oficial do USPTO
OXURION
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
21/07/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42, 44
Data de depósito
18/12/2018
Data de registro
10/12/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/06/2026
Última transação
21/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
32
Localização do titular
BE
Examinador
HARMON, RAYMOND E
Unidade examinadora
L30
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording "OXURION" in stylized text, where the letters "O" and "URION" are in blue and the "X" is in a larger, slanted font in green.
Titulares e representantes
Titulares
Oxurion
Representantes
Martin W. Schiffmiller Kirschstein Israel Schiffmiller & Pieron
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Biopharmaceutical preparations for use in the treatment of hypertensionstrokescardiac diseases and vascular diseases; diagnostic medical reagentschemicals preparations and biological materialsall the foregoing being in the form of spatially defined arrays and solutions and reagents for medical laboratory use in diagnosingmonitoringpredicting diseases and for measuring and predicting response to therapy of cardiac and vascular diseases; pharmaceutical preparations for use in the treatment of hypertensionstrokescardiac diseases and vascular diseases; pharmaceutical substances and medicines for treatment or prevention of eye disorders and diseases and of ophthalmological disorders and diseases; pharmaceutical preparations and substances for the treatment or prevention of diabetes; medicines for treating or preventing diabetes; ophthalmic medicines and surgical fluidsophthalmic pharmaceutical preparations; pharmaceutical eye drops
Classe 42
Scientific and technological servicesnamely research and design relating thereto in the field of ophthalmologyin the field of diabetes and in the field of treatment of cardiovascular diseasecardiac disease and vascular disease; industrial analysis of the pharmaceutical preparations of others used for the treatment of ophthalmologic diseasesdiabetes and cardiovascular diseases for quality control purposes; research services in the field of ophthalmologydiabetes and cardiovascular diseases; pharmaceutical and biopharmaceutical research and development; biopharmaceutical product evaluation; research in the field of treatment of cardiovascular diseasecardiac diseasevascular disease; development of new treatments for pathologies in which vascular biology plays a critical role in the field of biopharmaceuticals
Classe 44
Medical services; veterinary services; consultancy servicesconsultancy in the medicalveterinary and pharmaceutical treatment of patients in the fields of ophthalmologydiabetes and cardiovascular diseases; medical servicescardiac and vascular therapeuticprognostic and diagnostic testing services
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
26/02/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/01/2026
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
10/12/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/04/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
23/03/2020
FIMP
FINAL DISPOSITION PROCESSED
23/03/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/03/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
10/12/2019
GPNX
NOTIFICATION PROCESSED BY IB
05/10/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
24/09/2019
PUBO
PUBLISHED FOR OPPOSITION
24/09/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
18/09/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
18/09/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/09/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/08/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
16/08/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
16/08/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
16/08/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
16/08/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/07/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
22/07/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
22/07/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
22/07/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
22/07/2019
RFNT
REFUSAL PROCESSED BY IB
12/04/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
28/03/2019
RFRR
REFUSAL PROCESSED BY MPU
27/03/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
19/03/2019
CNRT
NON-FINAL ACTION WRITTEN
18/03/2019
MAFR
APPLICATION FILING RECEIPT MAILED
16/03/2019
DOCK
ASSIGNED TO EXAMINER
13/03/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/03/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/03/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace OXURION ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.